Patients Sought for New Trial of Adoptive Immunotherapy

CHICAGO—Researchers from three midwestern centers are seeking patients with leukemia, lymphoma, or multiple myeloma who have relapsed after an allogeneic stem cell transplant for a new trial of adoptive immunotherapy.

The concept of the study is that lymphocyte infusions from the original donor may induce remission. However, this approach may also be complicated by graft-versus-host disease (GVHD).

The researchers will attempt remission induction by infusion of IL-2-activated lymphocytes transduced with the herpes simplex thymidine kinase (HSTK) gene. If severe GVHD occurs, the infused lymphocytes will be killed by adminis-tration of the prodrug ganciclovir (Cytovene).

For referrals, contact Dr. Richard Burt at Northwestern University (312-908-5400), Dr. William Drobyski or Dr. William Burns at the Medical College of Wisconsin, Milwaukee (414-257-5452), or Dr. Charles Link at the Human Gene Therapy Research Institute, Des Moines, Iowa (515-241-8790).